(19)
(11) EP 1 663 343 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
04.12.2019 Bulletin 2019/49

(45) Mention of the grant of the patent:
23.10.2019 Bulletin 2019/43

(21) Application number: 04784410.5

(22) Date of filing: 15.09.2004
(51) International Patent Classification (IPC): 
A61M 25/00(2006.01)
A61L 31/16(2006.01)
 A61L 29/16(2006.01)
(86) International application number:
PCT/US2004/030541
(87) International publication number:
WO 2005/027996 (31.03.2005 Gazette 2005/13)

(54)

APPLICATION OF A THERAPEUTIC SUBSTANCE TO A TISSUE LOCATION USING AN EXPANDABLE MEDICAL DEVICE

APPLIKATION EINER THERAPEUTISCHEN SUBSTANZ AN EINE GEWEBESTELLE UNTER VERWENDUNG EINES EXPANDIERBAREN MEDIZINPRODUKTS

APPLICATION D'UNE SUBSTANCE THERAPEUTIQUE SUR UNE ZONE TISSULAIRE AU MOYEN D'UN DISPOSITIF MEDICAL EXTENSIBLE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL HR LT LV MK

(30) Priority: 15.09.2003 US 503359 P

(43) Date of publication of application:
07.06.2006 Bulletin 2006/23

(73) Proprietor: Atrium Medical Corporation
Merrimack, NH 03054 (US)

(72) Inventors:
  • HERWECK, Steve, A.
    Nashua, NH 03062 (US)
  • MARTAKOS, Paul
    Pelham, NH 03076 (US)
  • MOODIE, Geoffrey
    Hudson, NH 03051 (US)
  • LABRECQUE, Roger
    Londonderry, NH 03053 (US)
  • KARWOSKI, Theodore
    Hollis, NH 03049 (US)
  • CARLTON, Trevor
    Hudson, NH 03051 (US)

(74) Representative: Helbig, Christian et al
Wagner + Helbig Patentanwälte Pfarrstrasse 14
80538 München
80538 München (DE)


(56) References cited: : 
EP-B1- 1 007 135
WO-A2-00/32267
US-A- 5 490 839
US-A1- 2001 014 717
 WO-A1-03/039612
US-A- 4 702 252
US-A- 6 146 358
US-A1- 2002 165 423
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).